ABSTRACT OBJECTIVES This study assessed whether the benefit of sacubtril/valsartan therapy varied with clinical stability.
Solomon et al.
The PARADIGM-HF Trial Table 1 .
Participants with more recent HF hospitalizations Hazard ratio for primary endpoint (cardiovascular death or HF hospitalization) based on the presence of and time from a HF hospitalization prior to screening, adjusted for baseline characteristics which significantly differed across groups. HF ¼ heart failure.
FIGURE 2 Treatment Effect of Sacubitril/Valsartan Therapy
Forest plot shows treatment effects of sacubitril/valsartan (hazard ratio with 95% confidence interval) based on the presence of and time from a heart failure hospitalization prior to screening on the outcomes of cardiovascular death or heart failure hospitalization (left), cardiovascular death (middle), and all-cause mortality (right). Table 2) . We also saw no evidence that timing from prior hospitalization affected the likelihood of reaching target dose of enalapril and sacubitril/valsartan during the run-in phase of the trial (p ¼ 0.67).
DISCUSSION
We found that patients enrolled in PARADIGM-HF who had never had a prior HF hospitalization or had a remote HF hospitalization, arguably the most clinically stable patients enrolled, still had high absolute rates of CV death and of HF hospitalization during the course of the trial. In these stable patients, 51% of the first events experienced were CV death, and 60% of these deaths were sudden cardiac deaths. With respect to the risk of the primary endpoint and of CV death, the patients with no prior HF hospitalization or a remote HF hospitalization derived at least as much benefit from treatment with sacubitril/valsartan as with enalapril as did patients who were regarded as clinically less stable. These findings indicate that Values are n (%) or mean AE SD. *Average daily dose during double-blind period was divided by 20 mg for the enalapril arm and 400 mg for the sacubitril/valsartan arm.
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